Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.644
5.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals Holdings, Inc.
Total Equity
Reviva Pharmaceuticals Holdings, Inc.
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Reviva Pharmaceuticals Holdings, Inc.
NASDAQ:RVPH
|
Total Equity
-$10m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Equity
$70.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Equity
$17.1B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
1%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Equity
$87.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Equity
$44.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
0%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Equity
$14.2B
|
CAGR 3-Years
22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
-2%
|
|
Reviva Pharmaceuticals Holdings, Inc.
Glance View
Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. The company is headquartered in Cupertino, California and currently employs 5 full-time employees. The company went IPO on 2018-10-18. The firm discovers, develops and seeks to commercialize therapeutics for various diseases. Its pipeline focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics driven technology platform and chemistry to develop new medicines. Its pipeline has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Its primary focus is developing its lead product candidate, RP5063, for the treatment of schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), behavioral and psychotic symptoms, dementia or Alzheimer's disease (BPSD), Parkinson's disease psychosis (PDP), and attention deficit hyperactivity disorder (ADHD). RP5063 also focuses on the treatment of pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The firm's RP1208, is in pre-clinical development, which focuses on the treatment of depression and obesity.
See Also
What is Reviva Pharmaceuticals Holdings, Inc.'s Total Equity?
Total Equity
-10m
USD
Based on the financial report for Sep 30, 2024, Reviva Pharmaceuticals Holdings, Inc.'s Total Equity amounts to -10m USD.
What is Reviva Pharmaceuticals Holdings, Inc.'s Total Equity growth rate?
Total Equity CAGR 1Y
-17%
Over the last year, the Total Equity growth was -17%.
You don't have any saved screeners yet